decisionhealth Newsletters, Part B News - 2003 Issue 10 (October)
How to bill for drug treatment of prostate cancer
Subscribe or sign in to view the full article.
Article Overview
This article explains a Medicare billing comparison for drug treatment of prostate cancer and discusses how practices approach reimbursement for commonly used prostate cancer therapies. It is aimed at oncologists, urologists, billing staff, and compliance professionals who need to understand the general coding and payer-policy context surrounding these treatments.
Why This Topic Matters
The article matters because it highlights how reimbursement policy can affect practice payment decisions for prostate cancer drug administration and why payer rules may influence whether a practice administers the drug itself or uses an alternate arrangement.
What You Will Learn
- How the article frames Medicare billing for prostate cancer drug treatment
- Which broad coding categories are associated with the therapies discussed
- What types of payer policy considerations are mentioned in connection with reimbursement
- Which clinical specialties and practice roles are relevant to the billing discussion
Who Should Read This
- Oncologists
- Urologists
- Billing and coding staff
- Compliance managers
- Physician office administrators
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com